Shares of Salarius Pharmaceuticals (SLRX) were up over 151% Monday after the company said it and Decoy Therapeutics agreed to a merger deal to create a new company in which Salarius and Decoy investors will respectively hold 14% and 86% of the combined company's outstanding shares.
Salarius' wholly-owned unit will merge with Decoy and the newly formed company will operate as Decoy Therapeutics, according to the statement.
Decoy Chief Executive Officer Frederick Pierce, Chief Scientific Officer Barbara Hibne and Salarius' Chief Financial Officer Mark Rosenblum will be part of the combined company's leadership team.
Price: 3.93, Change: +2.37, Percent Change: +151.92
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。